Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021PRNewsWire • 06/07/21
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia VeraPRNewsWire • 06/03/21
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232PRNewsWire • 05/24/21
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021PRNewsWire • 05/12/21
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 05/04/21
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical MeetingPRNewsWire • 04/27/21
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines AgencyPRNewsWire • 03/22/21
Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/22/21
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/11/21
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdatePRNewsWire • 03/10/21
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial ResultsPRNewsWire • 03/03/21
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 03/02/21
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/04/21
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)PRNewsWire • 12/16/20
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 12/15/20
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common StockPRNewsWire • 12/11/20
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common StockPRNewsWire • 12/10/20
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population CategoriesPRNewsWire • 12/07/20
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia VeraPRNewsWire • 12/06/20
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020PRNewsWire • 11/30/20
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare ConferencePRNewsWire • 11/25/20
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare ConferencePRNewsWire • 11/11/20
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 11/04/20